Background. Cryptococcus can cause meningoencephalitis (CM) among previously healthy non-HIV adults. Spinal arachnoiditis is under-recognized, since diagnosis is difficult with concomitant central nervous system (CNS) pathology.
The yeast pathogen, Cryptococcus, causes central nervous system (CNS) infections in immunosuppressed individuals including those afflicted with human immunodeficiency virus (HIV), although 10%-20% of infections in the United States are in non-HIV, non-transplant adults without readily identifiable immunodeficiencies [1] [2] [3] [4] . Mortality may be up to 35%-50% in this latter population, partially due to delays in diagnosis resulting from often indolent clinical presentations and lack of fever in a host without obvious risk factors [2, 3, 5] . Although meningoencephalitis and cryptococcomas are the most common cryptococcal CNS syndromes, spinal arachnoiditis has also been reported in both immunocompromised [6, 7] and previously healthy patients [8] [9] [10] [11] . However, complexities in neurological assessment, resulting from both upper motor and lower motor neuron signs and symptoms may obscure the diagnosis, leading to under recognition. Specific to spinal anatomy, lumbar involvement may present with cauda equina or conus medullaris syndromes characterized by bladder dysfunction, lower back and/or leg pain (often bilateral), saddle sensory disturbances, and gait disturbance from lower extremity weakness and reflex abnormalities, which may be asymmetric. In addition, the presence of hydrocephalus or increased intracranial pressure further masks the diagnosis as it also complicates the neurological exam, given the often concomitant presence of symmetric lower extremity upper motor neuron signs, weakness, incontinence, and gait ataxia.
The understanding of human pathobiology of cryptococcal menigoencephalitis (CM) has recently incorporated an increased recognition of the role of host damage in infectious disease symptomatology [12, 13] . The role of the pathogen remains an important aspect leading to host damage and effective microbiological control is key to effective management. However, first with the recognition of immune reconstitution inflammatory syndrome (IRIS) resulting from anti-retroviral therapy in HIV [14] [15] [16] and later, a postinfectious inflammatory response syndrome (PIIRS) in previously healthy individuals [17] , there has been an increasing appreciation of the role of host-initiated immune damage in cryptococcal disease. However, lack of understanding of how pathogen and host damage effects play out under different clinical scenarios have led to a number of seemingly contradictory adjunctive therapies in refractory cases, including the use of rh-IFN-γ-1b as a T-cell augmenting therapy in HIV CM [18, 19] , corticosteroids in the initial presentation of HIV CM [20, 21] or after onset of cryptococcal IRIS [22, 23] . In previously healthy populations, despite guidelines suggesting consideration of interferon γ (IFNγ)-based adjunctive therapy in refractory cases [23] , anecdotal reports of steroid use further complicate treatment approaches in this complicated disease [24, 25] .
Thus, to better understand the pathobiology of cryptococcal human disease syndromes, we conducted a detailed clinical and immunological study of 6 cases of cryptococcal spinal arachnoiditis among a consecutive series of 26 previously healthy adults with CM.
METHODS

Patients
We performed a descriptive study of 6 patients with cryptococcal spinal arachnoiditis identified among 26 consecutively recruited and previously healthy patients with cryptococcal meningoencephalitis, using an institutional review board (IRB)-approved protocol (NIAID Protocol 93-I-0106). Although healthy donor (HD) controls were used as a comparator as previously described [26] , each patient also served as his/her own respective control comparing pre-and post-immunomodulatory interventions as noted below.
Clinical Evaluation
Neurologic and radiographic evaluations included gait and reflex assessment, urinary retention quantification via post-void residual (PVR) bladder ultrasound, and contrast-enhanced magnetic resonance imaging (MRI) of the lumbo-sacral spine. These were repeated throughout the clinical course. A neurologic score based on dichotomized dysfunction related to the cauda equina was developed based on the Scripps Neurologic Rating Scale, grouping symptoms into 3 broad categories of severity to enable quantified comparisons: Gait: 0 = walks independently; 1 = walks with assistance; 2 = unable to walk; LE Motor Ataxia: 0 = no ataxia; 1 = mild to moderate ataxia; 2 = severe ataxia/unable to walk; Bladder Incontinence: 0 = no incontinence; 1 = partial incontinence; 2 = complete incontinence [27, 28] . This was performed by our neurologist (O.K. , and MIP3β/CCL19), and biomarker analyses (NFL, sCD27, sCD14, and sCD21), as previously described [26, [29] [30] [31] .
Therapeutic Intervention
Methylprednisolone 1 gram intravenously for 7 days (pulse or "high dose" steroids), oral corticosteroid equivalent to prednisone 0.5 mg/kg/d ("moderate dose" corticosteroids), methotrexate 10 mg subcutaneously weekly, and/or tacrolimus (target trough 10-20 ng/mL) were utilized as indicated. Patients underwent post-therapeutic lumbar punctures for CSF examination to exclude microbiological recurrence by fungal culture and cryptococcal antigen (CrAg) (Meridian Diagnostics, Memphis, TN) and to evaluate intrathecal inflammation.
Statistics
Nonparametric Mann U Whitney test was used in unpaired comparisons. Spearman's ρ correlation, linear regression, and Wilcoxon matched pairs signed rank or Friedman (for more than 2 groups with repeated measures) P-values were calculated between clinical and CSF parameters to quantify significance of response to such therapies. Moreover, a "threshold" CSF/serum glucose for predicting "high NFL" (> 3036, based on the maximum NFL value from 6 non-CNS patients used as negative controls) was calculated, derived from the receiver operator curve (ROC) at the sensitivity = 1 and specificity = 0.5 cutoff. To test for an overall association between an inflammatory biomarker and NFL, we calculated a weighted average of each subject's Spearman correlation between the biomarker and NFL, with weights equal to the number of observations for each subject; a Monte Carlo permutation approach was used to test if these weighted average correlations were different from zero. Neurological scores were compared with "non-parametric ANOVA" (Friedman test) followed by Dunn's multiple comparisons test. All analyses were performed using JMP v.12.0.1 (SAS Institute Inc. Cary, NC) and PRISM v.6.05 (GraphPad Software Inc., La Jolla, CA).
The present study identified a group of 6 patients having a complication of spinal arachnoiditis out of a cohort of 26 consecutive patients recruited at the NIH clinical center as part of a study of cryptococcal CNS disease in previously healthy individuals without obvious risk factors. Five were diagnosed with arachnoiditis subsequent to their evaluation of their CNS disease (26) and one represented a new patient. Table 1 summarizes the findings of the 6 patients with one illustrative case described below.
Five were male and the median age was 49.5 [interquartile range (IQR): 31.75-59.0] years. Key diagnostic, co-localizing findings suggesting the diagnosis were asymmetric weakness, sensory defects and diminished reflexes on exam supporting lower-motor neuron involvement. Five presented with cognitive changes from accompanying meningoencephalitis, making diagnosis difficult, and 3 had gait instability. had CSF protein levels > 600 mg/dL. The 2 C. gattii cases were young men of Hispanic origin-one from southern California (VGIII) and the other from northern California (VGIIathe predominant strain in the Pacific Northwest outbreak), but neither possessed anti-GMCSF autoantibodies [32, 33] . Four patients had severe CNS pathology (eg, hydrocephalus) requiring ventriculoperitoneal shunts for sustained elevated intracranial pressures. At the time of diagnosis of spinal arachnoiditis, all had negative CSF fungal cultures after prior therapy with amphotericin B. Because of a concern that the syndrome reflected PIIRS, trials of adjunctive high-dose pulse corticosteroids were administered. Five (83.3%) showed clinical response (eg, gait) and median post-pulse PVR among all 6 decreased to 116.0 [IQR: 25.0-126.0] mL (Wilcoxon paired test, P = .25). Overall, we noted significant improvement in gait and balance up to 6 months after stopping pulse steroids with a neurological score change from a median of 4.0 to 0.9 (Wilcoxon paired test, P = .0005; Figure 2 ). Notable was case 1 that demonstrated the highest initial neurological defect (6.0) and residual defect following pulse corticosteroids (4.0) ( Figure 1) ; the residua likely related to his delay in diagnosis and corticosteroid treatment (1004 days vs. 186-423 days, respectively) ( Table 1) .
Case Example
A 23-year-old Hispanic male (Table 1 , case 2) developed night sweats, weakness, headache, and neck stiffness over 3 months. Contrast-enhanced brain MRI revealed a 1-cm lesion in the left basal ganglia with diffuse leptomeningeal enhancement. Repeated LP revealed persistently elevated intracranial pressures (opening pressure > 50 cm H 2 0) and grew Cryptococcus gattii (VGIII). His initial serum and CSF cryptococcal antigen were 1:128 and 1:256, respectively. A ventriculoperitoneal shunt was placed for hydrocephalus. He was treated with liposomal amphotericin B and flucytosine for 6 weeks, switching to voriconazole and then fluconazole subsequently. Repeated CSF cultures were negative. He then developed multiple episodes of urinary incontinence and asymmetric lower extremity weakness over the next month, despite his shunt functioning well. Neurologic examination showed diminished strength in the right lower extremity (4/5) and asymmetric deep tendon reflexes (ankles: right 2+ normal, left clonus). PVR was 260 mL. Spine MRI with gadolinium revealed clumping and thickening of the cauda equina ( Figure 1 , case 2), consistent with cryptococcal lumbar spinal arachnoiditis. Adjunctive pulse methylprednisolone 1 g intravenously daily for 7 days plus liposomal Amphotericin B led to the PVR reducing to 126 mL and resolution of lower extremity weakness. Subsequent attempts at a monthly pulse methylprednisolone dosing were initially successful but then rebound of his ataxic gait emerged 2 weeks after each dose. Consequently, he required a very slow steroid taper over 1 year. He eventually had a negligible PVR and was able to ambulate but had a residual wide-based gait.
To characterize the immune pathophysiology of these patients, we performed soluble CSF biomarker analyses before and after therapeutic interventions. Figure 4 , serial CSF measurements throughout treatment courses demonstrated a relationship in most cases between sCD27 and sCD21 and NFL, with positive significant Spearman's rho rank correlation in case 1. Overall, weighted average correlations were significant with 0.60 for sCD27 and NFL and 0.45 for sCD21 and NFL; the associated P-values were .002 and .03, respectively. In addition, we observed that a threshold CSF to serum glucose <0.59 also correlated significantly with NFL neuronal damage in previously healthy adults with cryptococcosis (Supplemental Figure 2A and 2B) [26, 34] . of immunoglobulin intrathecal synthesis, were also common in these patients, consistent with products of B-cell activation. Figure 5 shows summary longitudinal measurements of sCD27 and sCD21and NFL in relationship to high dose pulse corticosteroids. Overall, high-dose pulse corticosteroids had discernible effects on intrathecal inflammation (sCD27, sCD21, P = .06) with a positive rebound in inflammation evident after the pulse suggesting further that the post-pulse reductions were likely due to the corticosteroid intervention. Figure 6 also demonstrates the individual biomarker measurements after oral corticosteroids and steroid-sparing therapies such as tacrolimus or methotrexate. Additional CSF analysis in cases 1 and 2 (Supplemental Figure 3 ) demonstrated significant reductions in all 10 soluble pro-inflammatory cytokines tested including IL6 and the Th1-polarizing cytokine IFNγ and its induced chemokine, CXCL10. Ex vivo flow cytometry revealed a decrease in MyDC and PlDC, HLA-DR activated CD4+, CD8+ T lymphocytes and B lymphocytes occurred intrathecally in all cases after high dose steroids, compared with little changes in leukocyte subsets after oral moderate dose steroids, tacrolimus, or methotrexate ( Figure 6 and Supplemental Figure 4) . Post-therapy biomarker data are incomplete, because cases 2 and 4 developed severe posterior spinal sac adhesions that made safe sampling of CSF via the lumbar space unfeasible. However, similar to the other patients, case 4 had a poor clinical response to tacrolimus, despite a serum trough concentration of 12 ng/mL. In addition Table 1 ). Baseline studies, 2-9 months before pulse corticosteroids (Base), Pre-pulse corticosteroids (1-7 days before pulse) compared to immediate post treatment (7-14 days) to late comparison (2-6 months after pulse), N = 6 (Friedman, repeated measures, P = .0005); *0.01≤P < .05; **0.001≤P < .01; ***0.0001≤P < .001. CSF from multiple samplings over each patient's clinical course was assayed for sCD27, sCD14, sCD21, and NFL, as described in Methods, and then aggregated. To test for an overall association between an inflammatory biomarker and NFL, a weighted average of each subject's Spearman correlation between the biomarker and NFL was calculated, with weights equal to the number of observations for each subject. These weighted average correlations were 0.60 for sCD27 and NFL and 0.45 for sCD21 and NFL. A Monte Carlo permutation approach was used to test if these weighted average correlations were different from zero. The associated P-values were .002 for sCD27 and .028 for sCD21. Data are unavailable for case 4 due to inability to safely acquire CSF via lumbar space.
to the arachnoiditis, this patient developed a left middle cerebral vasculopathy followed by rupture. On autopsy of this one death in this cohort of 26, brain tissue tacrolimus levels were elevated at 64.8 + 8.3 (range from 3 samples: 59.3-74.3) ng/mL suggesting blood brain penetration was not a predominant cause of clinical failure in treatment of either the central or spinal process. Of note, a CSF tacrolimus level on case 5 was 0 ng/mL when his serum trough level was 13.5 ng/mL.
DISCUSSION
We report our experience of a series of 6 patients with cryptococcal spinal arachnoiditis in previously healthy adults as a complication of CM within a cohort of 26 consecutively recruited patients. Although prior reports [7, 8, 10, 11, 35, 36] focused on clinical and radiographic aspects, the present study utilized detailed CSF immunophenotyping to demonstrate the presence of PIIRS as well as a promising response to high dose corticosteroids. Although there was likely a referral bias toward more severe cases, the treatment of refractory cases is an important group to consider, considering the high mortality of cryptococcal disease in this population [2] .
Recognition of a spinal process in the setting of meningoencephalitis is complicated by meningitis-induced intracranial hypertension with resulting hydrocephalus presenting also with gait disturbance and urinary problems. However, intracranial hypertension is usually associated with hyperreflexia and spasticity, and absence of these neurological signs and the presence of saddle sensory disturbances suggest concomitant lower motor neuron dysfunction. Although pain characterizes most other causes of spinal arachnoiditis, 4 of our patients had no radiculopathy sensory symptoms [37] , suggesting this to be an unreliable sign in cryptococcal spinal arachnoiditis. Although severe manifestations are often perceived to be due to microbiologic failure, leading clinicians to repeatedly re-institute amphotericin B induction therapy, we have found clinical deterioration to be more closely associated with negative CSF cultures after treatment at the time of the arachnoiditis diagnosis.
PIIRS can be likened to IRIS among HIV-infected hosts during immunologic recovery with compartmentalized activation of intrathecal T cells in the setting of microbiological control. However, PIIRS differs from IRIS in having a discordant Th1 helper lymphocyte-M2 alternatively activated monocyte response [26] . In the present study, CSF cultures after amphotericin B treatment were sterile in all patients and accompanied by robust elevations in the soluble T-cell biomarker, sCD27, and the soluble B-cell biomarker, sCD21, consistent with intrathecal activation of adaptive immunity. Furthermore, elevations in these were positively associated with the axonal damage biomarker, NFL, suggesting that ongoing inflammation could participate in a causal pathway of neurological damage, a necessary requirement for a useful biomarker [38, 39] . To help in the management of such patients, we found that low CSF/serum glucose is associated with NFL, providing a readily available lab test to follow in the absence of more detailed CSF immunological testing.
Clinical responses to high-dose pulse corticosteroids were found to be associated with both significant reductions in neurological severity and inflammatory parameters, further suggesting a role for host inflammation induced neuronal damage in PIIRS. First, we found reduced intrathecal lymphocytes (CSF sCD27and sCD21) following pulse corticosteroids and rebound neuroinflammation after stopping the high dose therapies or switching to/from moderate dose oral steroids or tacrolimus, implicating the pulse in inflammatory suppression. Second, after high dose steroids, we noted reductions in proinflammatory cytokines such as IFN-γ, IL6, and CXCL10 and chemokines involved in the recruitment of T cells and monocytes such as CCL7, CCL2, CCL3, and CCL19 among 2 patients. Interestingly, though not shown, CSF sCD14, an activation biomarker for monocytes, was not strongly elevated and did not correlate with NFL. Lack of monocyte activation is consistent with previous data that identified predominantly M2 polarized macrophages in brain tissue of patients with PIIRS, which are not effective in clearing live fungi or nonviable fungal antigens [17, 26, 40] . However, the treatment results require caution in interpretation because of the small size of the series of this rare complication. As depicted in case 1, poor clinical responses to high dose pulse corticosteroids may be due to irreversible damage from fibrosis occurring after prolonged inflammation. This patient received pulse steroids more than 2 years after initial diagnosis, with relative lack of clinical response compared to the other cases that improved, receiving the pulse much earlier in their disease course (eg, case 6). Moreover, cumulative adverse events associated with prolonged corticosteroid therapy in this population due to defective antigen clearance and a prolonged inflammatory response [26] suggest an urgent need to identify effective steroid-sparing therapy.
In summary, we have presented the clinical, radiologic, and neuroimmunophenotypic characterization of a cohort of cryptococcal spinal arachnoiditis among 6 previously healthy adults with CM, emphasizing the clinical and pathophysiological manifestations of a post-infectious inflammatory condition in the process. Diagnosis remains challenging, given overlapping signs and symptoms from concomitant hydrocephalus and increased intracranial pressure from CM. Although preliminary data on the clinical and immunologic response to adjunctive immunosuppressive modalities such as pulse corticosteroids suggests a causal role of neuroinflammation in neuropathology, further trials are required to determine optimal treatment strategies to control inflammation over the long course of the disease.
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